Tidepath

Growth-hormone peptides

Sermorelin

Also called Geref

Once an FDA-approved drug, as Geref, now discontinued.

Status
Was FDA-approved, as Geref, until the approval was withdrawn in 2009.
Routes we have on file
By injection
Where doses come from
No checked dose range
Half-life
About 4 minutes after an infusion into a vein

What it is

Sermorelin is the active part of GHRH (growth-hormone-releasing hormone), the brain signal that tells the pituitary gland to release growth hormone. It was FDA-approved as Geref, including to treat children who weren't growing well and didn't make enough growth hormone. That product was later discontinued.

What makes it distinct

It was once approved, and there are older studies of it in people, including children with growth hormone deficiency. That label is discontinued, and Tidepath has no checked dose range for it.

Open questions

  • Sermorelin (plain GRF 1-29) and Mod GRF 1-29 (also called CJC-1295 without DAC; DAC is an add-on that keeps the other form of CJC-1295 in the blood for days) are different molecules, with some amino acids swapped, so Tidepath asks which you mean.
  • How long it lasts after injection under the skin (pharmacokinetics). One study measured a half-life (the time it takes for half a dose to clear) of about 4 minutes in 10 healthy men, after an infusion into a vein. None of our sources gives one for injection under the skin. Tidepath doesn't chart its levels.
  • Whether it builds muscle or improves sleep. It raises growth hormone, which is why it's grouped under both, but human studies haven't proven an effect on either.

More in Growth-hormone peptides